AC Immune SA (ACIU) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio (QTTB) has outperformed AC Immune SA (ACIU) over the past year, gaining 170.6% versus a loss of 27.6%. Over five years, ACIU leads with a -58.7% price change compared with -92.8% for QTTB. AC Immune SA is the larger company by market cap ($253.5 million vs $240.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | QTTB |
|---|---|---|
| Share price | $2.55 | $8.09 |
| Market cap | $253.54M | $240.83M |
| 1-day change | -0.78% | +1.25% |
| YTD return | -18.79% | +143.67% |
| 1-year return | -27.56% | +170.57% |
| 5-year return | -58.74% | -92.75% |
| P/E ratio (TTM) | — | 2.57 |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $23.57 |
| 52-week low | $2.10 | $1.91 |
| Distance from 52-week high | -36.25% | -65.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +234.12% | +389.49% |
| Average volume | 201.86K | 1.38M |
| Shares outstanding | 99.43M | 29.77M |
| Employees | 90 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed ACIU by 198.1 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
ACIU vs QTTB FAQ
Which is bigger, AC Immune SA or Q32 Bio?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $240.83M for Q32 Bio (QTTB).
Which stock has performed better over the past year, ACIU or QTTB?
QTTB returned +170.57% over the past 12 months, compared with -27.56% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.